<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Huo BN</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Voriconazole (VRZ) is involved in a variety of drug‒drug interactions (DDIs), but few studies have reported adverse events (AEs) associated with the DDIs of VRZ. The primary goal of this study was to analyse the potential risk factors for AEs caused by DDIs between VRZ and other drugs via the OpenVigil FDA platform and to provide a reference for preventing VRZ DDIs and monitoring clinically related adverse drug events.&lt;h4>Methods&lt;/h4>A retrospective pharmacovigilance study was conducted to investigate the AEs related to DDIs between VRZ and four categories of drugs: proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and other antibacterial drugs. AE information for the target drugs from the first quarter of 2004 to the thir</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1292163</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11471622</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.</pubmed_title><pmcid>PMC11471622</pmcid><pubmed_authors>Song L</pubmed_authors><pubmed_authors>Yin NG</pubmed_authors><pubmed_authors>Ai ML</pubmed_authors><pubmed_authors>Jia YT</pubmed_authors><pubmed_authors>Xiao JW</pubmed_authors><pubmed_authors>Huo BN</pubmed_authors><pubmed_authors>Shu L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.</name><description>&lt;h4>Background&lt;/h4>Voriconazole (VRZ) is involved in a variety of drug‒drug interactions (DDIs), but few studies have reported adverse events (AEs) associated with the DDIs of VRZ. The primary goal of this study was to analyse the potential risk factors for AEs caused by DDIs between VRZ and other drugs via the OpenVigil FDA platform and to provide a reference for preventing VRZ DDIs and monitoring clinically related adverse drug events.&lt;h4>Methods&lt;/h4>A retrospective pharmacovigilance study was conducted to investigate the AEs related to DDIs between VRZ and four categories of drugs: proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and other antibacterial drugs. AE information for the target drugs from the first quarter of 2004 to the thir</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-18T14:10:10.172Z</modification><creation>2025-04-04T19:38:30.537Z</creation></dates><accession>S-EPMC11471622</accession><cross_references><pubmed>39403147</pubmed><doi>10.3389/fphar.2024.1292163</doi></cross_references></HashMap>